Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (133)

2024

  1. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  2. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  3. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  4. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

  5. Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

    Blood Advances

  6. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

  7. Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry

    Haematologica

  8. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

    Blood Advances, Vol. 8, Núm. 18, pp. 4950-4959

2023

  1. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries

    Frontiers in Medicine, Vol. 10

  2. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

    Blood cancer journal

  3. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  4. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  5. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

    Blood, Vol. 142, Núm. 18, pp. 1518-1528

  6. Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II)

    Revista Espanola de Anestesiologia y Reanimacion, Vol. 70, Núm. 7, pp. 409-421

  7. Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II)

    Medicina Intensiva, Vol. 47, Núm. 8, pp. 454-467

  8. Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Cancer Medicine, Vol. 12, Núm. 4, pp. 3999-4009

  9. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840

  10. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100

  2. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68